Trails Edge Capital Partners, LP - 23 Dec 2025 SCHEDULE 13G Report for Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value (IKT)

Filing Manager
Trails Edge Capital Partners, LP
Reporting Manager
Trails Edge Capital Partners, LP
Security
Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value
Symbol
IKT
Shares outstanding
120,494,078 shares
Disclosed Ownership
6,145,198 shares
Ownership
5.1%
Form type
SCHEDULE 13G
Filing time
31 Dec 2025, 17:00:18 UTC
Date of event
23 Dec 2025
SEC
View on sec.gov

Reporting Managers (3)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Trails Edge Capital Partners, LP 5.1% 6,145,198 6,145,198 0 : Trails Edge Capital Partners, LLC, GP of Trails Edge Capital Partners, LP /s/ Ortav Yehudai Ortav Yehudai / Chief Investment Officer of Trails Edge Capital Partners, LLC
Trails Edge Biotechnology Master Fund, LP 5.1% 6,145,198 6,145,198 0 Trails Edge GP, LLC, GP of Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP /s/ Ortav Yehudai Ortav Yehudai / Chief Investment Officer of Trails Edge GP, LLC
Ortav Yehudai 5.1% 6,145,198 6,145,198 0 /s/ Ortav Yehudai Ortav Yehudai / Individual